Svitlana Tyekucheva

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL.

Ahn IE, Brander DM, Ren Y, Zhou Y, Tyekucheva S, Walker HA, Black R, Montegaard J, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng SY, Crombie J, Fisher DC, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Brown JR, Davids MS.

Blood Adv. 2024 Feb 27. 8(4):832-841. PMID: 38163317

Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00.

Rusakiewicz S, Tyekucheva S, Tissot-Renaud S, Chaba K, Imbimbo M, Benedetti F, Kammler R, Hornfeld J, Munzone E, Gianni L, Thurlimann B, Láng I, Pruneri G, Gray KP, Regan MR, Loi S, Colleoni M, Viale G, Kandalaft L, Coukos G, Curigliano G.

Eur J Cancer. 2024 Mar. 200:113535. PMID: 38309015

Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples.

Khalsa JK, Cha J, Utro F, Naeem A, Murali I, Kuang Y, Vasquez K, Li L, Tyekucheva S, Fernandes SM, Veronese L, Guieze R, Sasi BK, Wang Z, Machado JH, Bai H, Alasfour M, Rhrissorrakrai K, Levovitz C, Danysh BP, Slowik K, Jacobs RA, Davids MS, Paweletz CP, Leshchiner I, Parida L, Getz G, Brown JR.

Blood. 2023 08 03. 142(5):421-433. PMID: 37146250

A harmonized resource of integrated prostate cancer clinical, -omic, and signature features.

Laajala TD, Sreekanth V, Soupir AC, Creed JH, Halkola AS, Calboli FCF, Singaravelu K, Orman MV, Colin-Leitzinger C, Gerke T, Fridley BL, Tyekucheva S, Costello JC.

Sci Data. 2023 07 05. 10(1):430. PMID: 37407670

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.

Naeem A, Utro F, Wang Q, Cha J, Vihinen M, Martindale S, Zhou Y, Ren Y, Tyekucheva S, Kim AS, Fernandes SM, Saksena G, Rhrissorrakrai K, Levovitz C, Danysh BP, Slowik K, Jacobs RA, Davids MS, Lederer JA, Zain R, Smith CIE, Leshchiner I, Parida L, Getz G, Brown JR.

Blood Adv. 2023 05 09. 7(9):1929-1943. PMID: 36287227

The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer.

Ma C, Zhou Y, Fanelli GN, Stopsack KH, Fiorentino M, Zadra G, Mucci LA, Loda M, Tyekucheva S, Penney KL.

Mol Cancer Res. 2023 03 01. 21(3):253-260. PMID: 36511902

Cross-Study Replicability in Cluster Analysis.

Masoero L, Thomas E, Parmigiani G, Tyekucheva S, Trippa L.

Stat Sci. 2023 May. 38(2):303-316. PMID: 37885824

Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kd inhibitors.

Gadi D, Martindale SP, Chiu PY, Khalsa J, Chen PH, Fernandes SM, Wang Z, Tyekucheva S, Machado JH, Fisher DC, Armand P, Davids MS, Rodig S, Sherry B, Brown JR.

Blood Cancer J. 2023 02 02. 13(1):22. PMID: 36732326

A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.

Ryan CE, Brander DM, Barr PM, Tyekucheva S, Hackett LR, Collins MC, Fernandes SM, Ren Y, Zhou Y, McDonough MM, Walker HA, McEwan MR, Abramson JS, Jacobsen ED, LaCasce AS, Fisher DC, Brown JR, Davids MS.

Leukemia. 2023 04. 37(4):835-842. PMID: 36717653

curatedPCaData: Integration of clinical, genomic, and signature features in a curated and harmonized prostate cancer data resource.

Laajala TD, Sreekanth V, Soupir A, Creed J, Calboli FC, Singaravelu K, Orman M, Colin-Leitzinger C, Gerke T, Fidley BL, Tyekucheva S, Costello JC.

bioRxiv. 2023 Jan 19. PMID: 36711769